Alpha 2.0
Login Register
» Articles » PMID: 20146086

High Dose Weekly Erlotinib Achieves Therapeutic Concentrations in CSF and is Effective in Leptomeningeal Metastases from Epidermal Growth Factor Receptor Mutant Lung Cancer

Overview
Journal J Neurooncol
Publisher Springer
Date 2010 Feb 11
PMID 20146086
Citations 107
Authors
Jennifer L Clarke
William Pao
Nian Wu
Vincent A Miller
Andrew B Lassman
Affiliations
Soon will be listed here.
Abstract

Leptomeningeal metastases (LM) occur in 5-10% of patients with solid tumors and are associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a mutation in the epidermal growth factor receptor (EGFR) gene that confers sensitivity to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib. The CSF concentration of EGFR-TKIs achieved by standard daily dosing may be insufficient for therapeutic effect. However, intermittent (pulsatile) high dose administration (1000-1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient.

Citing Articles

Advancing leptomeningeal metastases treatment in -mutated non-small cell lung cancer: lessons from the BLOSSOM trial.

Bortolot M, Huijs J, Brandsma D, Compter A, van Geel R, Hendriks L Transl Lung Cancer Res. 2025; 14(1):7-13.

PMID: 39958217 PMC: 11826264. DOI: 10.21037/tlcr-24-1006.

Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature.

Hachlaf M, Lkhoyaali S, Nadir W, Lemsyeh H, El Ghissassi B, Mrabti H J Med Case Rep. 2024; 18(1):374.

PMID: 39113087 PMC: 11308728. DOI: 10.1186/s13256-024-04706-w.

Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases....

van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M Neuro Oncol. 2024; 26(12):2316-2327.

PMID: 39110039 PMC: 11630515. DOI: 10.1093/neuonc/noae138.

Drug delivery in leptomeningeal disease: Navigating barriers and beyond.

Arshad N, Biswas N, Gill J, Kesari S, Ashili S Drug Deliv. 2024; 31(1):2375521.

PMID: 38995190 PMC: 11249152. DOI: 10.1080/10717544.2024.2375521.

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.

Bian D, Lazaratos A, Maritan S, Quaiattini A, Zeng Z, Zhu Z Heliyon. 2024; 10(9):e29668.

PMID: 38698967 PMC: 11064091. DOI: 10.1016/j.heliyon.2024.e29668.

References
1.
Shah N, Kasap C, Weier C, Balbas M, Nicoll J, Bleickardt E . Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008; 14(6):485-93. DOI: 10.1016/j.ccr.2008.11.001. View
2.
Jackman D, Holmes A, Lindeman N, Wen P, Kesari S, Borras A . Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006; 24(27):4517-20. DOI: 10.1200/JCO.2006.06.6126. View
3.
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View
4.
Dhruva N, Socinski M . Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol. 2009; 27(22):e31-2. DOI: 10.1200/JCO.2008.21.0963. View
5.
Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View